Navigation Links
Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs

ing of our drug candidates. These statements involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2006, our quarterly reports filed on Form 10-Q and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of June 20, 2007. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

Contact

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
ir@arraybiopharma.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:8/1/2014)... NEW YORK , Aug. 1, 2014 /PRNewswire/ ... , the largest, independent manufacturer of phosgene and ... , today announced that it has acquired Framochem ... based in Hungary . ... product offerings and creates one of the world,s ...
(Date:8/1/2014)... LAKE FOREST, Ill. , Aug. 1, 2014 ... private equity firm focused exclusively on the healthcare ... Inc. ("Vesta") to The Lubrizol Corporation ("Lubrizol"). Lubrizol, ... company that produces and supplies technologies to customers ... Terms of the transaction were not disclosed. ...
(Date:8/1/2014)... , Aug. 1, 2014 ... of the "Global Medical Biosensors Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Medical biosensors ... help of physicochemical detectors. These biosensors monitor health ... invasive and non-invasive methods. They are cost-effective and ...
Breaking Medicine Technology:VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2
... Jan. 18 ,Exelixis, Inc. (Nasdaq: EXEL ) ... exercise its option to license XL784 for further,development ... meet its primary endpoint in a phase 2 ... in one subgroup were encouraging,Exelixis believes that the ...
... Specialty Pharmacy, one,of the largest privately owned national ... an agreement with Genzyme Corporation to,administer their 2008 ... the world,s largest biotechnology companies dedicated to products,and ... transplant, and oncology., Diplomat will be the ...
Cached Medicine Technology:GSK Does Not Option XL784 for Further Development 2GSK Does Not Option XL784 for Further Development 3Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program 2
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... 01, 2014 Summer is here, and with ... during the summer, and they can be a pain for ... to help all their customers get rid of ticks and ... 6,000 eggs in the summer, which is why they are ... tall grass and woodland areas and carry a number of ...
(Date:8/1/2014)... The American Telemedicine Association (ATA) lauds ... Peter Welch (D-VT), for their latest actions to ... of 2014, which improves telemedicine coverage in Medicare. ... healthcare access and affordability using telecommunications technology," said ... cost-saving provisions are critical to improve telehealth coverage ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... others such as Zinc Oxide, Titanium Dioxide, and ... Building & Construction, Food & Beverages, Textiles, and ... ROW) - Global Trends and Forecasts to 2018" ... market drivers, opportunities, and trends in the diverse ...
(Date:8/1/2014)... August 01, 2014 The North America ... security solutions market in North America with analysis and ... from around $3.53 billion in 2014 to $4.77 billion ... to 2019. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... Taking menstrual cycle into account when booking exam may cut ... (HealthDay News) -- Using a blood test to pinpoint the ... menstrual cycles could reduce the need for repeat scans, U.S. ... MRI scans during the follicular phase (days 3 to14) of ...
... simple blood test corresponding to the follicular phase (days ... optimal scheduling of breast MRI exams in premenopausal women ... repeat scans and non-diagnostic tests patients experience and providing ... to a study published in the December issue of ...
... Virginia Commonwealth University Massey Cancer Center and VCU Institute ... may play a pivotal role in two processes that ... metastasis. Scientists hope the finding could lead to an ... this gene resulting in inhibition of cancer growth. ...
... alcohol dependence problems drink significantly more than do younger adults ... The findings suggest that older problem drinkers may have developed ... than younger abusers to achieve the effects they seek. ... 60 who have alcohol dependence drink more than 40 alcoholic ...
... , NORTHBROOK, Ill., Nov. 20 ... one of the fastest growing cosmetic skin care providers ... injections, Zerona(TM) laser treatments and SmartLipo(TM) body contouring at ... cosmetics industry, new innovations and technologies are constantly being ...
... Mallika Chopra, healthy living expert and founder and CEO ... products in the US, are teaming up to help Americans ... with advice from Chopra, to be posted today on Intent.com. ... the stress or foreboding that typically comes with this time ...
Cached Medicine News:Health News:Blood Test Could Boost Clarity of Breast MRI Results for Some 2Health News:Researchers identify role of gene in tumor development, growth and progression 2Health News:Older problem drinkers use more alcohol than do their younger counterparts 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 3Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 3
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Perfect for use in the E.R. Stabilizes collateral ligament strains in seconds and allows hand and finger function. Made from 1/8" AliPlast™ PXE. Can be scissor trimmed....
... Control of thumb motion can be difficult ... for persons with spinal cord injuries and ... to cerebral palsy or other motor or ... the thumb for control and coordination. Soft ...
... ThumWrap Splints offer support without the restriction ... mild pain or strain due to repetitive ... the rigid or the flexible stay to ... Washable and breathable, the ThumWrap Splint is ...
Medicine Products: